AOP Health International Management, a European pioneer in integrated therapies for rare diseases and in critical care, agreed to acquire the remaining shares in Shield Therapeutics, a patient-focused, commercial-stage pharmaceutical company, for £33.5m. AOP and Shield have entered into the Relationship Agreement pursuant to which AOP has agreed amongst other things to permit Shield to continue to be able to operate independently of AOP.